



#6

Attorney Docket: 1064/48505
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marc G. ACHEN et al.

Serial No.: 09/761,636

Filed: January 18, 2001

Title: VEGF-D/VEGF-C/VEGF PEPTIDOMIMETIC INHIBITOR

STATEMENT UNDER 37 C.F.R. 1.821(f)

Commissioner for Patents
Washington, DC 20231

Sir:

Please replace the computer readable form (CRF) copy of the sequence listing and corresponding written sequence listing filed January 18, 2001 with the attached substitute CRF and substitute written sequence listing. This substitution is due to a format error on the original CRF. The undersigned hereby states that the contents of the paper copy of the substitute sequence listing and the accompanying substitute computer readable copy of the sequence listing are the same. This submission includes no new matter.

Respectfully submitted,

May 29, 2001

W. D. Evans

J. D. Evans

Registration No. 26,269

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 628-8800
Facsimile No.: (202) 628-8844

09/761,636-052901



SEQUENCE LISTING

<110> ACHEN, Marc
 STACKER, Steven
 HUGHES, Richard
 CENDRON, Angela

<120> VEGF-D/VEGF-C/VEGF PEPTIDOMIMETIC INHIBITOR

<130> 1064/48505 Achen et al

<150> US 60/176,293

<151> 2000-01-18

<150> US 60/204,590

<151> 2000-05-16

<160> 34

<170> PatentIn version 3.0

<210> 1

<211> 96

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Amino acid residues of Val101-Pro196 of VEGF-D

<400> 1

Val Ile Asp Glu Glu Trp Gln Arg Thr Gln Cys Ser Pro Arg Glu Thr
 1 5 10 15

Cys Val Glu Val Ala Ser Glu Leu Gly Lys Ser Thr Asn Thr Phe Phe
 20 25 30

Lys Pro Pro Cys Val Asn Val Phe Arg Cys Gly Gly Cys Cys Asn Glu
 35 40 45

Glu Ser Leu Ile Cys Met Asn Thr Ser Thr Ser Tyr Ile Ser Lys Gln
 50 55 60

Leu Phe Glu Ile Ser Val Pro Leu Thr Ser Val Pro Glu Leu Val Pro
 65 70 75 80

Val Lys Val Ala Asn His Thr Gly Cys Lys Cys Leu Pro Thr Ala Pro

85

90

95

<210> 2
 <211> 94
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Amino acid residues Lys42-Asp135 of VEGF165

<400> 2
 Lys Phe Met Asp Val Tyr Gln Arg Ser Tyr Cys His Pro Ile Glu Thr
 1 5 10 15
 Leu Val Asp Ile Phe Gln Glu Tyr Pro Asp Glu Ile Glu Tyr Ile Phe
 20 25 30
 Lys Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Asp
 35 40 45
 Glu Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Leu Thr Met Gln
 50 55 60
 Ile Met Arg Ile Lys Pro His Gln Gly Gln His Ile Gly Glu Met Ser
 65 70 75 80
 Phe Leu Gln His Asn Lys Cys Glu Cys Arg Pro Lys Lys Asp
 85 90

<210> 3
 <211> 73
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Amino acid residues Val101-Thr173 of VEGF-D

<400> 3
 Val Ile Asp Glu Glu Trp Gln Arg Thr Gln Cys Ser Pro Arg Glu Thr
 1 5 10 15
 Cys Val Glu Val Ala Ser Glu Leu Gly Lys Ser Thr Asn Thr Phe Phe
 20 25 30
 Lys Pro Pro Cys Val Asn Val Phe Arg Cys Gly Gly Cys Cys Asn Glu
 35 40 45

```
<210> 7
<211> 11
<212> PRT
<213> Homo sapiens
```

<400> 7

Cys Ile Ser Val Pro Leu Thr Ser Val Pro Cys
 1 5 10

<210> 8

<211> 17

<212> PRT

<213> Homo sapiens

<400> 8

Cys Ala Ser Glu Leu Gly Lys Ser Thr Asn Thr Phe Cys Lys Pro Pro
 1 5 10 15

Cys

<210> 9

<211> 9

<212> PRT

<213> Homo sapiens

<400> 9

Cys Cys Asn Glu Glu Ser Leu Ile Cys
 1 5

<210> 10

<211> 9

<212> PRT

<213> Homo sapiens

<400> 10

Cys Ser Val Pro Leu Thr Ser Val Cys
 1 5

<210> 11

<211> 7

<212> PRT

<213> Homo sapiens

<400> 11

Cys Val Pro Leu Thr Ser Cys
 1 5

<210> 12

<211> 6
 <212> PRT
 <213> Homo sapiens

<400> 12
 Cys Val Pro Leu Thr Cys
 1 5

<210> 13
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 13
 Cys Ile Ser Val Pro Leu Ser Val Pro Cys
 1 5 10

<210> 14
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 14
 Cys Ile Ser Val Pro Leu Val Pro Cys
 1 5

<210> 15
 <211> 13
 <212> PRT
 <213> synthetic construct

<400> 15
 Cys Ala Thr Glu Leu Gly Lys Ser Thr Asn Thr Phe Cys
 1 5 10

<210> 16
 <211> 13
 <212> PRT
 <213> synthetic construct

<400> 16
 Cys Ala Ser Glu Leu Gly Lys Thr Ser Asn Thr Phe Cys
 1 5 10

<210> 17
 <211> 13
 <212> PRT
 <213> synthetic construct

<400> 17
 Cys Ala Ser Asp Val Gly Lys Ser Thr Asn Thr Trp Cys
 1 5 10

<210> 18
 <211> 13
 <212> PRT
 <213> synthetic construct

<400> 18
 Cys Ala Ser Glu Leu Gly Arg Ser Thr Asn Ser Phe Cys
 1 5 10

<210> 19
 <211> 8
 <212> PRT
 <213> synthetic construct

<400> 19
 Cys Asn Asp Glu Ser Leu Leu Cys
 1 5

<210> 20
 <211> 8
 <212> PRT
 <213> synthetic construct

<400> 20
 Cys Asn Glu Glu Thr Leu Ile Cys
 1 5

<210> 21
 <211> 8
 <212> PRT
 <213> synthetic construct

<400> 21
 Cys Asn Glu Asp Ser Phe Ile Cys

SCANNED, # 12

1

5

<210> 22
 <211> 8
 <212> PRT
 <213> synthetic construct

<400> 22
 Cys Asn Glu Glu Ser Val Val Cys
 1 5

<210> 23
 <211> 11
 <212> PRT
 <213> synthetic construct

<400> 23
 Cys Leu Ser Val Pro Leu Thr Ser Val Pro Cys
 1 5 10

<210> 24
 <211> 11
 <212> PRT
 <213> synthetic construct

<400> 24
 Cys Ile Thr Ile Pro Leu Thr Ser Leu Pro Cys
 1 5 10

<210> 25
 <211> 11
 <212> PRT
 <213> synthetic construct

<400> 25
 Cys Ile Ser Leu Pro Ile Ser Ser Val Pro Cys
 1 5 10

<210> 26
 <211> 11
 <212> PRT
 <213> synthetic construct

<400> 26

Cys Val Ser Val Pro Leu Thr Thr Val Pro Cys
 1 5 10

<210> 27

<211> 17

<212> PRT

<213> synthetic construct

<400> 27

Cys Ala Thr Glu Leu Gly Lys Ser Thr Asn Thr Phe Cys Lys Pro Pro
 1 5 10 15

Cys

<210> 28

<211> 17

<212> PRT

<213> synthetic construct

<400> 28

Cys Ala Ser Glu Leu Gly Lys Thr Ser Asn Thr Phe Cys Lys Pro Pro
 1 5 10 15

Cys

<210> 29

<211> 17

<212> PRT

<213> synthetic construct

<400> 29

Cys Ala Ser Asp Val Gly Lys Ser Thr Asn Thr Trp Cys Lys Pro Pro
 1 5 10 15

Cys

<210> 30

<211> 17

<212> PRT

<213> synthetic construct

<400> 30

Cys Ala Ser Glu Leu Gly Arg Ser Thr Asn Ser Phe Cys Lys Pro Pro
 1 5 10 15

SCANNED, # 12

Cys

<210> 31
 <211> 17
 <212> PRT
 <213> synthetic construct

<400> 31
 Cys Ala Ser Glu Leu Gly Lys Ser Thr Asn Thr Tyr Cys Lys Pro Pro
 1 5 10 15

Cys

<210> 32
 <211> 17
 <212> PRT
 <213> synthetic construct

<400> 32
 Cys Ala Ser Glu Leu Gly Arg Ser Thr Asn Ser Phe Cys Lys Pro Pro
 1 5 10 15

Cys

<210> 33
 <211> 9
 <212> PRT
 <213> synthetic construct

<400> 33
 Cys Cys Asn Asp Glu Ser Leu Leu Cys
 1 5

<210> 34
 <211> 9
 <212> PRT
 <213> synthetic construct

<400> 34
 Cys Cys Asn Glu Glu Thr Val Ile Cys
 1 5